KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Non-Current Deferred Tax Liability (2016 - 2025)

Historic Non-Current Deferred Tax Liability for Pfizer (PFE) over the last 17 years, with Q3 2025 value amounting to $2.5 billion.

  • Pfizer's Non-Current Deferred Tax Liability rose 1431.88% to $2.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 billion, marking a year-over-year increase of 1431.88%. This contributed to the annual value of $2.1 billion for FY2024, which is 8687.86% down from last year.
  • Pfizer's Non-Current Deferred Tax Liability amounted to $2.5 billion in Q3 2025, which was up 1431.88% from $2.5 billion recorded in Q2 2025.
  • Over the past 5 years, Pfizer's Non-Current Deferred Tax Liability peaked at $16.2 billion during Q4 2023, and registered a low of $328.0 million during Q4 2021.
  • Over the past 5 years, Pfizer's median Non-Current Deferred Tax Liability value was $2.2 billion (recorded in 2024), while the average stood at $3.3 billion.
  • Per our database at Business Quant, Pfizer's Non-Current Deferred Tax Liability crashed by 9277.85% in 2021 and then skyrocketed by 14253.49% in 2025.
  • Pfizer's Non-Current Deferred Tax Liability (Quarter) stood at $7.7 billion in 2021, then increased by 23.4% to $9.5 billion in 2022, then surged by 69.89% to $16.2 billion in 2023, then plummeted by 86.88% to $2.1 billion in 2024, then grew by 16.26% to $2.5 billion in 2025.
  • Its last three reported values are $2.5 billion in Q3 2025, $2.5 billion for Q2 2025, and $2.3 billion during Q1 2025.